Intuitive Surgical (ISRG) Stock Forecast & Price Target

Intuitive Surgical is forecasting strong growth in procedure volume, with an estimate of 13.5%-15.5% Y/Y for FY26 compared to the previous estimate of 13%-15%, surpassing analyst expectations of 14.6%. This growth is driven by the increasing adoption of its Da Vinci systems, particularly the Dv5 and Ion systems, which have seen significant growth in procedures performed per system. Overall, this demonstrates a strong demand for minimally invasive surgery, and we expect Intuitive Surgical's revenue and earnings to continue to outperform the market. The company's financial performance in the first quarter of 2026 was impressive, with revenue of $2.771B (22.9% Y/Y) and adjusted EPS of $2.50, exceeding both analyst and company expectations. This was driven by strong procedure growth of 17% Y/Y, with the Dv5 and Ion systems leading the way with 16% and 39% Y/Y growth, respectively. The company also raised its FY26 guidance for procedure growth and adjusted gross margins, demonstrating its strong position in the minimally invasive surgery market. Intuitive Surgical's focus on innovation and building out its ecosystem bodes well for future growth. The company's Dv5 and Ion systems have both

Intuitive Surgical is experiencing strong top-line growth and record margins, with continued strong demand for its da Vinci surgical systems, indicating a potentially positive outlook. However, the company's high valuation and the potential for increased competition in the robotic surgery market could weigh on future growth and profitability, leading to a negative outlook. Additionally, the recent dip in interest and other income could indicate potential financial challenges for the company.